Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

nal Formulary, which is a list of products generally covered under VA pharmacy benefits.
  • On March 4, 2013, the company entered into an agreement with Laboratorios Grifols, S.A., for the development, manufacture and supply of commercial quantities of OFIRMEV in flexible plastic bags. Cadence plans to submit a supplemental NDA to the FDA in the second half of 2013 seeking approval of the product to be manufactured by Grifols.
  • In January 2013, Cadence received a total of $14.6 million from the waiver of its option to purchase Incline Therapeutics, Inc., and the sale of the shares of Incline stock held by Cadence, resulting in a gain of $7.7 million.
  • On February 22, 2013, Cadence amended its existing supply agreement for OFIRMEV with Lawrence Laboratories, a member of the Bristol-Myers Squibb Company group of companies, extending the term of the Agreement through December 2018.
  • On March 6, 2013, Cadence and Baxter Healthcare Corporation announced the termination of the development and supply agreement for OFIRMEV between the two companies.
  • "In the first quarter we delivered strong sales growth, strengthened our balance sheet and solidified our supply chain for OFIRMEV. Our extended relationship with Lawrence Laboratories and agreement with Grifols to develop flexible plastic bags for OFIRMEV should enable us to meet increasing customer demand for OFIRMEV," said Ted Schroeder, President and CEO of Cadence.

    Financial ResultsCadence's net product revenue was $23.6 million for the three months ended March 31, 2013, which represents an increase of $15.6 million from the $8.0 million in net product revenue reported for the three months ended March 31, 2012. As of January 1, 2013, Cadence began to recognize revenue at the time that product is sold to a wholesaler, consistent with other companies with products at this stage of commercialization. Previously, revenue was recognized only when wholesalers sold the product to t
    '/>"/>

    SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
    2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
    3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
    4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
    5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
    6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
    7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
    8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
    9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
    10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
    11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... ... August 27, 2015 , ... Proove ... new data on the relationship of genetics and hypertension at the International ... Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive overview ...
    (Date:8/26/2015)... 2015  The Diabetes Research Institute (DRI), a ... Miller School of Medicine, announced today that the ... for the first time a novel transplant technique ... approved Phase I/II study builds upon decades of ... important first step toward the development of the ...
    (Date:8/26/2015)... , August 26, 2015 After litigating ... Europlasma NV relating to P2i United States ... their dispute in the United States ... the part of either party. As a result of the ... of California dismissed the case without ...
    (Date:8/25/2015)... ... August 25, 2015 , ... ... tissue lesions are cancerous is described by University of Illinois researchers in the ... optics and photonics. , In “ Breast cancer diagnosis using spatial light interference ...
    Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4
    ... Effective Localized Pain Management, NESHER, Israel, October ... the US Food and Drug Administration (FDA),has granted ... device,used to treat pain. PainShield is the first ... new dimension in ultrasound,treatment of pain and soft ...
    ... Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... Shizuko Sei of SAIC-Frederick,Inc., delivered a poster ... of Intravenously Administered Oncolytic Reovirus in,Nude Mice ... EORTC-NCI-AACR,Symposium on Molecular Targets and Cancer Therapeutics. ...
    ... Corporation (Nasdaq: UTHR ) announced today that ... before market open on,Thursday, October 30, 2008., ... Thursday,October 30, 2008, at 9:00 a.m. Eastern Time. ... callers dialing,1-706-679-8129. A rebroadcast of the teleconference will ...
    Cached Biology Technology:NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device 2Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium 2Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium 3
    (Date:7/31/2015)... 31 de julio de 2015 La 10 th ... celebrará por medio de BGI del 22 al 25 de octubre ... Este año, la conferencia celebra su décimo aniversario. ... convertido en una de las reuniones anuales más influyentes del ... las reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
    (Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
    (Date:7/30/2015)... VIEW, Calif. , July 30, 2015 /PRNewswire/ ... and services for gene function analysis and biomarker ... Guide RNA (sgRNA) Knockout Library targeting all human ... specifically and permanently "knock out" a gene,s function. ... provides a high throughput screening tool so that ...
    Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
    ... , Apoptosis, programmed cell death, is essential to ... prevention. The process dramatically transforms cellular structures but ... much about this structural reorganization a mystery. , ... the current issue of Proceedings of the ...
    ... 2010 [Vienna, Austria] The appalling lack of access to ... including sex workers, men who have sex with men ... scale up of simple and inexpensive treatment regimens to ... rights violations that threaten future progress on AIDS, according ...
    ... is associated with significantly elevated rates of heart disease in ... published in this month,s issue of the journal Child ... had been physically abused as children had 45 per cent ... not been abused, despite the fact we had adjusted for ...
    Cached Biology News:How do cells die? Biophotonic tools reveal real-time dynamics in living color 2How do cells die? Biophotonic tools reveal real-time dynamics in living color 3Lack of access to evidence-based HIV prevention and care is a fundamental violation of human rights 2Lack of access to evidence-based HIV prevention and care is a fundamental violation of human rights 3Lack of access to evidence-based HIV prevention and care is a fundamental violation of human rights 4U of T researchers find link between childhood physical abuse and heart disease 2
    MagSi monodispers, magnetic silica particles with modified surface for SO3 coupling chemistry....
    Recognizes a full-length CLC-2 voltage-gated Cl- protein and not with other known proteins tested so far....
    Monoclonal Anti-Gα o purified immunoglobulin buffered aqueous solution Solution in phosphate buffered saline pH 7.4, containing 0.08% sodium azide. partially purified bovine brain Gα O ...
    Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
    Biology Products: